LIVINGSTONE HEALTH HOLDINGS LIMITED

(Incorporated in the Republic of Singapore)
(Company Registration Number 200404283C)

ISSUANCE AND ALLOTMENT OF DEFERRED CONSIDERATION SHARES PURSUANT TO ACQUISITION OF PHOENIX MEDICAL GROUP

The board of directors ("**Board**" or "**Directors**") of Livingstone Health Holdings Limited (the "**Company**", and together with its subsidiaries, the "**Group**") refers to the announcements made by the Company in relation to, *inter alia*, the acquisition of the PMG Group on 15 July 2024, 25 July 2024, 29 July 2024 and 1 August 2024 (the "**Previous Announcements**"). Unless otherwise defined, all terms and references used herein shall bear the same meanings ascribed to them in the Previous Announcements.

Introduction

As announced by the Company on 25 July 2024, the Company had on 24 July 2024 received the listing and quotation notice from the SGX-ST for the listing and quotation of 47,616,465 new shares in the capital of the Company, to be issued pursuant to the Proposed Acquisition (the "**Consideration Shares**"), which includes the 23,808,232 Consideration Shares to be issued subsequent to the Acquisition Completion Date.

Issuance and Allotment of Deferred Consideration Shares

The Board is pleased to announce that pursuant to the Acquisition Agreement, and as referenced in the Previous Announcements, an aggregate of 14,284,939 Consideration Shares (the "**Deferred Consideration Shares**") have been issued and allotted to the Counterparties today.

The Deferred Consideration Shares will rank *pari passu* in all respects with the existing shares of the Company, except that they will not be entitled to any dividends, rights, allotments or other distributions, the record date for which falls before the date of issue of the Deferred Consideration Shares.

The Deferred Consideration Shares are expected to be listed and quoted on the Catalist Board of the SGX-ST on 5 August 2025 and trading of the Deferred Consideration Shares is expected to commence from 9.00 a.m. on the same date. The approval in-principle granted by SGX-ST for the listing and quotation of the Deferred Consideration Shares is not to be taken as an indication of the merits of the Proposed Acquisition, the Deferred Consideration Shares, the Company, its subsidiaries and/or their securities.

Following the issue and allotment of the Deferred Consideration Shares, the total number of issued and paid-up ordinary share capital of the Company has increased to 628,600,844 shares (excluding treasury shares and subsidiary holdings).

By Order of the Board

Dr Tay Ching Yit, Wilson
Executive Director and Chief Executive Officer
1 August 2025

*This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited (the "**Sponsor**"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Lee Khai Yinn (Telephone: (65) 6232 3210) at 1 Robinson Road, #21-01, AIA Tower, Singapore 048542.